



CONTACT | Media:

+31.20.550.4488 (Amsterdam), +32.2.509.1392 (Brussels)

+351.217.900.029 (Lisbon), +44.20.7379.2789 (London)

+1.212.656.2411 (New York), +33.1.49.27.11.33 (Paris)

NYSE Euronext welcomes Movetis N.V. to its European market

The largest IPO in Europe of a pharmaceutical company since December 2007

Brussels, 4 December 2009 – Movetis, a Belgian pharmaceutical company, today listed on NYSE Euronext's Brussels market under the symbol « MOVE ».

A total of 19,994,359 Movetis shares were admitted to trading on NYSE Euronext at an introductory price of EUR 12.25 each. The listing resulted from the offer of 13,055,583 existing shares and 6,938,776 new shares, before exercise of the over-allotment option. The amount raised by the initial public offering was EUR 85 million, excluding the over-allotment corresponding to EUR 12.75 million.

At the opening, the first market price rose 2.9% to EUR 12.60, bringing the market capitalization of the company at EUR 252 million.

Vincent Van Dessel, CEO of NYSE Euronext, Brussels said: *'We are delighted to welcome Movetis on to NYSE Euronext. This great addition to our market hopefully signals a lasting rebound in the primary market and confirms Brussels as a leading market for biotech and pharmaceutical companies.'*

Dirk Reyn, CEO of Movetis added: *'Movetis is very satisfied with the success of its IPO and is very pleased to be listed on NYSE Euronext as it will enable the company to reach out to an even bigger investment community. It is the start of a new phase in Movetis' development as a company following the approval in the European Economic Area (EEA) of its lead product Resolor in October of this year.'*

Press contact: +32 2 509 13 92

About Movetis:

Movetis (www.movetis.com) Movetis, a spin-off, was founded in Belgium in November 2006 by senior managers and scientists of former Janssen Pharmaceutica NV (an affiliate of Johnson & Johnson).

Movetis is a rapidly growing European specialty pharmaceutical company focused on the discovery, development and commercialisation of novel innovative drugs for the treatment of gastrointestinal diseases with high unmet need. The Company's lead product Resolor® (prucalopride) has recently received marketing approval from the European Commission for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. Movetis expects the first launch of Resolor in Q1 2010.

About NYSE Euronext

NYSE Euronext (NYSE) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With more than 8,000 listed issues, NYSE Euronext's equities markets -- the New York Stock Exchange, NYSE Euronext, NYSE Amex and NYSE Alternext as well as NYSE Arca -- represent nearly 40 percent of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, the leading European derivatives business and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the S&P 100 index and Fortune 500. For more information, please visit: <http://www.nyx.com>